These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 35620456)

  • 1. Cost-effectiveness Analysis of Lorlatinib in Patients Previously Treated with Anaplastic Lymphoma Kinase Inhibitors for Non-small Cell Lung Cancer in Greece.
    Gourzoulidis G; Zisimopoulou O; Boubouchairopoulou N; Michailidi C; Lowry C; Tzanetakos C; Kourlaba G
    J Health Econ Outcomes Res; 2022; 9(1):50-57. PubMed ID: 35620456
    [No Abstract]   [Full Text] [Related]  

  • 2. Lorlatinib as a first-line treatment of adult patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer: Α cost-effectiveness analysis in Greece.
    Gourzoulidis G; Zisimopoulou O; Liavas A; Tzanetakos C
    Expert Rev Pharmacoecon Outcomes Res; 2024 Mar; 24(3):375-385. PubMed ID: 37997764
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost‑Effectiveness of Lorlatinib in First-Line Treatment of Adult Patients with Anaplastic Lymphoma Kinase (ALK)‑Positive Non‑Small‑Cell Lung Cancer in Sweden.
    Naik J; Beavers N; Nilsson FOL; Iadeluca L; Lowry C
    Appl Health Econ Health Policy; 2023 Jul; 21(4):661-672. PubMed ID: 37173513
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Cost-Effectiveness of Lorlatinib Versus Chemotherapy as a Second- or Third-Line Treatment in Anaplastic Lymphoma Kinase (ALK)-Positive Non-small-cell Lung Cancer in Sweden.
    Nilsson FOL; Asanin ST; Masters ET; Iadeluca L; Almond C; Cooper M; Smith S
    Pharmacoeconomics; 2021 Aug; 39(8):941-952. PubMed ID: 34080140
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-Effectiveness of Lorlatinib for the Treatment of Adult Patients with Anaplastic Lymphoma Kinase Positive Advanced Non-Small Cell Lung Cancer in Spain.
    Presa M; Vicente D; Calles A; Salinas-Ortega L; Naik J; García LF; Soto J
    Clinicoecon Outcomes Res; 2023; 15():659-671. PubMed ID: 37701861
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-Effectiveness of Lorlatinib as a First-Line Therapy for Untreated Advanced Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer.
    Li S; Li J; Peng L; Li Y; Wan X
    Front Oncol; 2021; 11():684073. PubMed ID: 34136409
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of ensartinib, crizotinib, ceritinib, alectinib, brigatinib and lorlatinib in patients with anaplastic lymphoma kinase-positive non-small cell lung cancer in China.
    Luo X; Zhou Z; Zeng X; Peng L; Liu Q
    Front Public Health; 2022; 10():985834. PubMed ID: 36211665
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of first-line versus second-line use of brigatinib followed by lorlatinib in patients with ALK-positive non-small cell lung cancer.
    Liu W; Huo G; Chen P
    Front Public Health; 2024; 12():1213318. PubMed ID: 38435286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness analysis of ceritinib vs. crizotinib in previously untreated anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) in Hong Kong.
    Loong HH; Wong CKH; Leung LKS; Chan CPK; Chang A; Zhou ZY; Xie J; Gibbs M
    Cost Eff Resour Alloc; 2020 Nov; 18(1):50. PubMed ID: 33292314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of ceritinib in previously untreated anaplastic lymphoma kinase-positive metastatic non-small cell lung cancer in the United States.
    Zhou ZY; Mutebi A; Han S; Bensimon AG; Louise Ricculli M; Xie J; Dalal A; Culver K
    J Med Econ; 2018 Jun; 21(6):577-586. PubMed ID: 29458286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.
    Solomon BJ; Besse B; Bauer TM; Felip E; Soo RA; Camidge DR; Chiari R; Bearz A; Lin CC; Gadgeel SM; Riely GJ; Tan EH; Seto T; James LP; Clancy JS; Abbattista A; Martini JF; Chen J; Peltz G; Thurm H; Ou SI; Shaw AT
    Lancet Oncol; 2018 Dec; 19(12):1654-1667. PubMed ID: 30413378
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Systematic Review of the Cost-Effectiveness Analyses of Anaplastic Lymphoma Kinase (ALK) Inhibitors in Patients with Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC).
    Chayab L; Konstantelos N; Leighl NB; Tadrous M; Wong WWL
    Pharmacoeconomics; 2023 Aug; 41(8):945-980. PubMed ID: 37268866
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The cost-effectiveness of brigatinib in adult patients with ALK inhibitor-naive ALK-positive non-small cell lung cancer from a US perspective.
    Cranmer H; Kearns I; Young M; Humphries MJ; Trueman D
    J Manag Care Spec Pharm; 2022 Sep; 28(9):970-979. PubMed ID: 36001099
    [No Abstract]   [Full Text] [Related]  

  • 14. Cost-effectiveness of ceritinib in patients previously treated with crizotinib in anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer in Canada.
    Hurry M; Zhou ZY; Zhang J; Zhang C; Fan L; Rebeira M; Xie J
    J Med Econ; 2016 Oct; 19(10):936-44. PubMed ID: 27149298
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lorlatinib for advanced anaplastic lymphoma kinase-positive non-small cell lung cancer: Results of the IFCT-1803 LORLATU cohort.
    Baldacci S; Besse B; Avrillon V; Mennecier B; Mazieres J; Dubray-Longeras P; Cortot AB; Descourt R; Doubre H; Quantin X; Duruisseaux M; Monnet I; Moro-Sibilot D; Cadranel J; Clément-Duchêne C; Cousin S; Ricordel C; Merle P; Otto J; Schneider S; Langlais A; Morin F; Westeel V; Girard N
    Eur J Cancer; 2022 May; 166():51-59. PubMed ID: 35278825
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-Effectiveness Analysis of 6 Tyrosine Kinase Inhibitors as First-Line Treatment for ALK-Positive NSCLC in China.
    Zhang M; Zheng B; Yang W; Jiang H; Sun X; Zhao Z; Li G; Dong H
    Clin Med Insights Oncol; 2024; 18():11795549241257234. PubMed ID: 38827520
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>50%) metastatic squamous and non-squamous non-small cell lung cancer in France.
    Chouaid C; Bensimon L; Clay E; Millier A; Levy-Bachelot L; Huang M; Levy P
    Lung Cancer; 2019 Jan; 127():44-52. PubMed ID: 30642550
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lorlatinib Effectiveness and Quality-of-Life in Patients with ALK-Positive NSCLC Who Had Failed Second-Generation ALK Inhibitors: Canadian Real-World Experience.
    Rupp M; Fanton-Aita F; Snow S; Wheatley-Price P; Melosky B; Juergens RA; Chu Q; Blais N; Banerji S; Ng R; Khoudigian S; Sharma A; On PV; Liu G
    Curr Oncol; 2023 Jul; 30(7):6559-6574. PubMed ID: 37504341
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of first-line treatments for patients with advanced anaplastic lymphoma kinase mutated, non-small cell cancer: A systematic review and network meta-analysis.
    Peng Y; Zhao Q; Liao Z; Ma Y; Ma D
    Cancer; 2023 Apr; 129(8):1261-1275. PubMed ID: 36748799
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost Effectiveness of Tofacitinib for the Treatment of Active Ankylosing Spondylitis in Greece.
    Gourzoulidis G; Solakidi A; Psarra M; Nikitopoulou E; Tzanetakos C
    Clin Drug Investig; 2024 Jan; 44(1):59-69. PubMed ID: 38104048
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.